CDC Antibodies

CDC antibodies, specifically targeting Complement-Dependent Cytotoxicity (CDC), are crucial in immunological assays and therapeutic applications. These antibodies trigger the classical complement pathway, leading to cell lysis in the presence of complement proteins. They are commonly used in research, diagnostics, and therapeutic development to investigate immune responses involving complement activation. CDC antibodies typically bind to surface antigens on target cells and recruit the complement system, culminating in membrane attack complex (MAC) formation, causing cell death.

Content of CDC Antibodies

CDC antibodies are typically monoclonal or polyclonal and are designed to either directly induce CDC activity or be used as tools for complement-based assays. They work by recognizing antigens on the cell surface and subsequently activating the complement cascade. This results in the formation of the MAC, which leads to cell lysis. CDC antibodies are commonly derived from species such as mice, rats, or rabbits, depending on their specific application.

Application of CDC Antibodies

• Therapeutic Development: In cancer immunotherapy, CDC antibodies are used to mediate the destruction of tumor cells by targeting specific antigens on their surface and engaging the complement system to induce cytotoxicity. Therapeutic monoclonal antibodies, such as Rituximab (anti-CD20), utilize CDC as one of their mechanisms of action.
• Immunological Research: CDC antibodies are valuable in studying immune mechanisms, particularly in understanding how the complement system contributes to immune surveillance and pathogen elimination. They are also used in the characterization of complement pathway deficiencies and disorders like paroxysmal nocturnal hemoglobinuria (PNH).
• Diagnostic Assays: CDC-based antibodies are employed in flow cytometry and cell-based assays to assess complement activity, as well as to evaluate the efficacy of therapeutic antibodies that activate the complement system. They are used in assays to quantify cell lysis rates and are integral in developing diagnostic tools for autoimmune diseases where the complement system plays a pathogenic role.

These antibodies have extensive applications in both preclinical research and clinical settings, particularly in designing complement-based therapies and diagnostic assays.